Integra LifeSciences slides after lowering annual forecasts

By Reuters News

** Integra LifeSciences IART.O shares fall 14.6% to $13.74 — lowest since May 11

** The medical equipment maker lowers FY26 revenue outlook to $1.63 bln-$1.65 bln from prior view $1.65 bln-$1.70 bln

** Cuts FY adj. EPS forecast to $2.30-$2.40 from $2.40-$2.50

** Trims Q3 revenue forecast to $410 mln-$412 mln from $410 mln-$425 mln

** Says July flooding at Cincinnati facility hurt Q3 revenue by ~$7 mln; sees $15 mln-$20 mln impact on Q4 revenue

** Expects full manufacturing to resume in Q227

** Three of 12 brokerages rate the stock "buy" or higher, seven "hold" and two "sell" or lower; median PT $19 - LSEG-compiled data

** Including session's move, stock up 10.4% YTD

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.